Clinical Options for the Reduction of Elevated Intraocular Pressure

Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease.1 Options for reducing IOP rely on pharmacological agents, laser treatments and surgery which may be pene...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawley, Laura, Zamir, Sohaib M., Cordeiro, Maria F., Guo, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619493/
https://www.ncbi.nlm.nih.gov/pubmed/23650457
http://dx.doi.org/10.4137/OED.S4909
_version_ 1782265489300389888
author Crawley, Laura
Zamir, Sohaib M.
Cordeiro, Maria F.
Guo, Li
author_facet Crawley, Laura
Zamir, Sohaib M.
Cordeiro, Maria F.
Guo, Li
author_sort Crawley, Laura
collection PubMed
description Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease.1 Options for reducing IOP rely on pharmacological agents, laser treatments and surgery which may be penetrating or non-penetrating. The last twenty years has seen significant changes in all of these strategies. This review aims to cover these clinical options and introduce some of the new technologies currently in development for the clinical lowering of IOP.
format Online
Article
Text
id pubmed-3619493
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-36194932013-05-06 Clinical Options for the Reduction of Elevated Intraocular Pressure Crawley, Laura Zamir, Sohaib M. Cordeiro, Maria F. Guo, Li Ophthalmol Eye Dis Review Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease.1 Options for reducing IOP rely on pharmacological agents, laser treatments and surgery which may be penetrating or non-penetrating. The last twenty years has seen significant changes in all of these strategies. This review aims to cover these clinical options and introduce some of the new technologies currently in development for the clinical lowering of IOP. Libertas Academica 2012-04-30 /pmc/articles/PMC3619493/ /pubmed/23650457 http://dx.doi.org/10.4137/OED.S4909 Text en © 2012 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Crawley, Laura
Zamir, Sohaib M.
Cordeiro, Maria F.
Guo, Li
Clinical Options for the Reduction of Elevated Intraocular Pressure
title Clinical Options for the Reduction of Elevated Intraocular Pressure
title_full Clinical Options for the Reduction of Elevated Intraocular Pressure
title_fullStr Clinical Options for the Reduction of Elevated Intraocular Pressure
title_full_unstemmed Clinical Options for the Reduction of Elevated Intraocular Pressure
title_short Clinical Options for the Reduction of Elevated Intraocular Pressure
title_sort clinical options for the reduction of elevated intraocular pressure
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619493/
https://www.ncbi.nlm.nih.gov/pubmed/23650457
http://dx.doi.org/10.4137/OED.S4909
work_keys_str_mv AT crawleylaura clinicaloptionsforthereductionofelevatedintraocularpressure
AT zamirsohaibm clinicaloptionsforthereductionofelevatedintraocularpressure
AT cordeiromariaf clinicaloptionsforthereductionofelevatedintraocularpressure
AT guoli clinicaloptionsforthereductionofelevatedintraocularpressure

Ejemplares similares